secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2026-07-31T11:51:32+00:00
Accession:  0001551152-26-000023
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie Q2 2026: adj. EPS $3.65 (+22.9% YoY), revenue $16.99B (+10.2%); announces $10.9B Apogee acquisition
--------------------------------------------------------------------------------

- GAAP diluted EPS $2.03 (+290.4% YoY); adjusted diluted EPS $3.65 (+22.9% YoY); includes $0.17 IPR&D impact.
- Net revenues $16.99B (+10.2% reported, +9.5% operational); Immunology $8.786B (+15.1%) led by Skyrizi $5.505B (+24.4%).
- Neuroscience $3.228B (+20.3%); Oncology $1.650B (-1.5%); Aesthetics $1.282B (+0.3%).
- Announces definitive agreement to acquire Apogee Therapeutics for ~$10.9B equity value; expected close Q3 2026.
- Updates 2026 adj. EPS guidance to $13.87-$14.07 (from $13.91-$14.11); includes $0.14 dilutive impact from Apogee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/0001551152-26-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260731.htm
  HTML page:      https://secwatch.observer/filing/0001551152-26-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer